Gala Pharmaceutical Inc.: 10-Q filed 2019-04-30
What Gala Pharmaceutical Inc. reported in its quarterly report filed 2019-04-30 (fiscal Q1 2019): 29 published measures, 62 facts as tagged in accession 0001683168-19-001231.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-04-30
- Fiscal period
- fiscal Q1 2019
- Accession
- 0001683168-19-001231 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Gala Pharmaceutical Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 282,633 | USD | |
| At 2018-11-30 | 262,158 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 1,633,091 | USD | |
| At 2018-11-30 | 1,120,864 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | -1,280,771 | USD | |
| At 2018-11-30 | -811,233 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 179,293 | USD | |
| At 2018-11-30 | 116,198 | USD | |
| At 2018-02-28 | 168 | USD | |
| At 2017-11-30 | 7,767 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | -577,172 | USD | 90 |
| 2017-12-01 to 2018-02-28 | -583,242 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | -107,702 | USD | 90 |
| 2017-12-01 to 2018-02-28 | -82,599 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 6,703 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 0 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 177,500 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 75,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | -6,703 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | -5,654,618 | USD | |
| At 2018-11-30 | -5,077,446 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 39,140 | USD | |
| At 2018-11-30 | 35,160 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 243,493 | USD | |
| At 2018-11-30 | 226,998 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 27,007 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 18,238 | USD | 90 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 230,663 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 548,228 | USD | 90 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 0 | USD | |
| At 2018-11-30 | 0 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 0 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 0 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 95,197,976 | shares | |
| At 2018-11-30 | 92,011,666 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 4,352,635 | USD | |
| At 2018-11-30 | 4,290,722 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | -1,350,458 | USD | |
| At 2018-11-30 | -858,706 | USD | |
| At 2017-11-30 | -905,820 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 58,152 | USD | |
| At 2018-11-30 | 35,160 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-02-28 | 19,012 | USD | |
| At 2018-11-30 | 0 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | -599,386 | USD | 90 |
| 2017-12-01 to 2018-11-30 | -1,906,350 | USD | 365 |
| 2017-12-01 to 2018-02-28 | -583,242 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 38,666 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 36,263 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 2,723 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 2,730 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | -368,723 | USD | 90 |
| 2017-12-01 to 2018-02-28 | -35,014 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 0 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-12-01 to 2019-02-28 | 0 | USD | 90 |
| 2017-12-01 to 2018-02-28 | 0 | USD | 90 |
Inspect the source
- Entity
- Gala Pharmaceutical Inc. / CIK 0001513403
- Captured
- SEC response SHA-256
3d1db4681c9d9a4cd1ba58e701ccbc4c56e8be5f9d6000e0517ef1300b358a33
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001513403.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))